FRA:77V (China)
Â
Ordinary Shares
€
0.55
+0.025 (+4.76%)
Jul 3
Business Description
Jacobio Pharmaceuticals Group Co Ltd
ISIN : KYG4987A1094
Share Class Description:
FRA:77V: Ordinary SharesTotal Employee Number:
196Compare
Compare
Traded in other countries / regions
01167.Hong Kong77V.GermanyJBPHF.USA IPO Date
2024-06-25Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.68 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -1.29 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.95 | |||||
Beneish M-Score | -1.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -18.8 | |||||
3-Year EBITDA Growth Rate | 33.3 | |||||
3-Year EPS without NRI Growth Rate | 24.3 | |||||
3-Year FCF Growth Rate | 12.9 | |||||
3-Year Book Growth Rate | -16.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.8 | |||||
9-Day RSI | 69.87 | |||||
14-Day RSI | 60.37 | |||||
3-1 Month Momentum % | -40.92 | |||||
6-1 Month Momentum % | -30.46 | |||||
12-1 Month Momentum % | -8.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.1 | |||||
Quick Ratio | 5.1 | |||||
Cash Ratio | 4.88 | |||||
Days Sales Outstanding | 152.17 | |||||
Days Payable | 45797.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 0.76 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.88 | |||||
Operating Margin % | -312.12 | |||||
Net Margin % | -274.04 | |||||
EBITDA Margin % | -242.12 | |||||
FCF Margin % | -397.68 | |||||
OCF Margin % | -394.57 | |||||
ROE % | -17.3 | |||||
ROA % | -11.19 | |||||
ROIC % | -72.84 | |||||
3-Year ROIIC % | 2373.4 | |||||
ROC (Joel Greenblatt) % | -95.75 | |||||
ROCE % | -12.1 | |||||
Moat Score | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 7.72 | |||||
PS Ratio | 69.33 | |||||
PB Ratio | 4.81 | |||||
Price-to-Tangible-Book | 5 | |||||
EV-to-EBIT | -20.42 | |||||
EV-to-Forward-EBIT | 4.68 | |||||
EV-to-EBITDA | -21.07 | |||||
EV-to-Revenue | 51.02 | |||||
EV-to-Forward-Revenue | 3.31 | |||||
EV-to-FCF | -12.81 | |||||
Price-to-GF-Value | 2.5 | |||||
| Price-to-Net-Current-Asset-Value | 6.11 | |||||
| Price-to-Net-Cash | 6.88 | |||||
Earnings Yield (Greenblatt) % | -4.9 | |||||
FCF Yield % | -5.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jacobio Pharmaceuticals Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.467 | ||
| EPS (TTM) (€) | -0.023 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 114.01 | ||
| 14-Day RSI | 60.37 | ||
| 14-Day ATR (€) | 0.024156 | ||
| 20-Day SMA (€) | 0.4825 | ||
| 12-1 Month Momentum % | -8.87 | ||
| 52-Week Range (€) | 0.422 - 1.13 | ||
| Shares Outstanding (Mil) | 783.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jacobio Pharmaceuticals Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jacobio Pharmaceuticals Group Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jacobio Pharmaceuticals Group Co Ltd Frequently Asked Questions
What is Jacobio Pharmaceuticals Group Co Ltd(FRA:77V)'s stock price today?
The current price of FRA:77V is €0.55. The 52 week high of FRA:77V is €1.13 and 52 week low is €0.42.
When is next earnings date of Jacobio Pharmaceuticals Group Co Ltd(FRA:77V)?
The next earnings date of Jacobio Pharmaceuticals Group Co Ltd(FRA:77V) is .
Does Jacobio Pharmaceuticals Group Co Ltd(FRA:77V) pay dividends? If so, how much?
Jacobio Pharmaceuticals Group Co Ltd(FRA:77V) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Jacobio Pharmaceuticals Group Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers